Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsSierra Health and Life PDL Coverage & Prior Auth |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentsierra health and lifePolicy N/A

    Essential 4-Tier Prescription Drug List (PDL) — Pharmacy Coverage Criteria

    Customize your policy alerts

    Sign up for all sierra health and life policy alerts

    Know when sierra health and life releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    PDL governing pharmacy benefit coverage tiers, prior authorization, and coverage notes for Sierra Health and Life medical plan members enrolled in the Essential 4-Tier PDL; applies to medications and informs members and providers about formulary status and coverage requirements.

    Policy Summary
    Payersierra health and life
    PolicyEssential 4-Tier Prescription Drug List (PDL) — Pharmacy Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug is marked with PA before dispensing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4tiers described
    May 1, 2026PDL effective date
    call/member websitecheck current coverage
    PA, QL, ST, SPcommon requirement flags
    partialdocument part

    Formulary Coverage & Tiering

    Tier-based coverage

    Coverage and tiering decisions

    Tier assignment and coverage logic: Medications are placed into tiers representing member cost-sharing and the plan's assessment of overall value; Tier 1 = lower‑cost (mostly generics), Tiers 2–3 = mid‑range cost (mix of brand and generic), Tier 4 = highest‑cost (mostly brand) and may have lower value alternatives.

    Where differences exist, the benefit plan documents control coverage; use plan documents to determine member cost-share and coverage applicability.

    Formulary entries with administrative controls

    Coverage and administrative controls are expressed per-line as Tier and Requirements & Limits

    Formulary entry structure: Each formulary line associates a drug name with a Drug Tier and Requirements & Limits flags (examples: PA = prior authorization, QL = quantity limit, SP = specialty, ST = step therapy, NF = non‑formulary).

    When a line lists PA, QL, SP, or ST, providers must follow the plan's administrative processes (e.g., submit prior authorization documentation or adhere to quantity limits).

    Policy Summary
    Payersierra health and life
    PolicyEssential 4-Tier Prescription Drug List (PDL) — Pharmacy Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug is marked with PA before dispensing.
    SourceLink
    On This Page
    Formulary Coverage & TieringProcedure & Billing CodesProvider Requirements, Prior Authorization & DocumentationKey Terms & AbbreviationsStep Therapy Policies & Affected ProductsQuantity Limits & Affected ProductsSpecialty Pharmacy & Site-of-Care ManagementBackground & Rationale

    Some medications may be excluded from coverage or designated non-formulary when a lower-cost covered option or an over-the-counter alternative is available. Coverage decisions reflect an assessment of total value, including clinical effectiveness, safety, and cost; when therapeutically equivalent but less costly options exist, only the lower-cost product may be covered. Members and providers should consult the member benefit plan documents and the plan member website to confirm whether a specific medication is excluded or requires an alternative product.

    Medications used for termination of pregnancy are governed by the member's medical benefit plan rather than the standard prescription drug benefit. Providers and members should review the applicable medical plan documents or call the number on the member ID card to determine coverage, exclusions, and cost-sharing for these products.

    Within the provided formulary excerpt there are no explicit exclusion statements or determinations that any listed product is "not medically necessary." The lines shown assign Drug Tier levels and annotate Requirements & Limits (for example, PA, QL, SP, NF), but do not include standalone medical necessity denials in these chunks.

    The excerpt does not contain clinical coverage criteria or medical necessity rules; it lists therapeutic headings, tier assignments, and administrative requirement flags (e.g., PA, QL, SP) for individual formulary lines. For clinical justification or detailed medical necessity criteria, providers must refer to the specific drug policy sections or the payer's benefit plan documents.

    No entries in the provided excerpt assert 'not medically necessary' findings; the content is limited to drug listings with tier and requirements annotations rather than explicit coverage denials or clinical-necessity language.

    Procedure & Billing Codes

    Coding (None in excerpt)
    Coding present in excerptNone — no procedure, diagnosis, or billing codes are listed in this segment
    Source noteDocument excerpt contains formulary rows and requirement flags but no CPT/HCPCS/ICD codes
    Implication for billingProviders should refer to specific drug policy sections or medical benefit documents for applicable procedure or diagnosis codes

    Provider Requirements, Prior Authorization & Documentation

    Prior Authorization

    Prior authorization may be required

    Prior authorization (PA) may be required for some medications and in situations where state mandates apply (for example, infertility coverage). Providers must submit PA requests when the formulary designates PA to access covered benefits for the member.

    Prior Authorization

    PA required for selected formulary drugs

    Numerous formulary products are marked with 'PA' in the Requirements & Limits field; providers must obtain prior authorization for these listed drugs before dispensing to ensure coverage.

    Prior Authorization

    PA required for specified entries

    Many individual formulary entries include 'Requirements & Limits' that list 'PA' — prior authorization is required for those specific products as shown on the drug list.

    Prior Authorization

    PA required for select antiviral/hepatitis agents

    Several antiviral/hepatitis agents (examples: HARVONI, LEDIPASVIR‑SOFOSBUVIR, SOFOSBUVIR‑VELPATASVIR, MAVYRET, VOSEVI) are shown with 'PA' (and often QL/SP/ST) in Requirements & Limits; prior authorization must be obtained before dispensing.

    Prior Authorization

    Prior authorization indicated on flagged entries

    Formulary flags show that several drugs require prior authorization (PA); providers must submit PA where entries are flagged to determine coverage.

    Prior Authorization

    PA required for select anticoagulant/biologic agents

    Multiple anticoagulant and related biologic products are labeled with 'PA' in their Requirements & Limits; providers must obtain prior authorization for these specified agents prior to dispensing.

    Prior Authorization

    PA required for PA‑designated drugs

    Numerous listed drugs show 'PA' in Requirements & Limits; providers must submit prior authorization requests per the payer process for any product so designated.

    Prior Authorization

    PA required for selected specialty/biologic agents

    Many specialty and biologic agents (examples: NGENLA, NORDITROPIN FLEXPRO, OMNITROPE, ORENCIA products, RINVOQ, OLUMIANT, SKYRIZI, TREMFYA) are marked with 'PA' (often along with QL, ST, or SP); prior authorization is required before coverage is approved.

    Prior Authorization

    PA required for high‑tier/specialty drugs

    Prior authorization is required for numerous high‑tier and specialty medications shown in the listing; obtain PA for products annotated with 'PA' to secure coverage.

    Prior Authorization

    PA required for specific agents

    Specific agents in the respiratory and other categories (examples include NUCALA, ADEMPAS, OPSUMIT, TYVASO, SODIUM OXYBATE, WAKIX, XYWAV) are listed with 'PA' — providers must obtain prior authorization for these products.

    Note

    No PA information in this fragment

    This fragment contains no prior authorization statements; refer to the specific drug listings or the member’s benefit documents for PA requirements.

    Note

    Index — no PA details

    This excerpt is an index only and does not include prior authorization details or affected codes; consult the referenced drug pages for PA requirements.

    Note

    Index has no PA rules

    The index section does not provide prior authorization rules; providers must consult the specific formulary or drug policy sections for PA requirements.

    Step Therapy

    Step therapy enforced via PA; document prior trials

    Step therapy (ST) requires trying one or more other medications before the requested medication may be covered and is enforced via prior authorization; providers must document trials of required agents when ST is indicated.

    Step Therapy

    Follow step‑number sequencing where shown

    Some formulary entries include explicit step numbers (e.g., nicotine 'step 1/2/3') indicating progression through step therapy; follow the plan‑specific step sequence where listed.

    Step Therapy

    Document prior therapy for ST‑flagged drugs

    Entries flagged 'ST' on the formulary indicate step therapy applies to those drugs; prescribers must document failure, contraindication, or intolerance to required prior agents when requesting coverage.

    Step Therapy

    ST present for select agents (document trials)

    When 'ST' appears in Requirements & Limits for listed products (examples include HARVONI and LEDIPASVIR‑SOFOSBUVIR), prior trials of preferred agents must be documented on PA submissions.

    Step Therapy

    ST may require trial of preferred agents

    Some formulary entries include ST flags meaning a lower‑tier or preferred agent trial is required before the requested drug will be approved; providers should include evidence of prior therapy in the PA documentation.

    Step Therapy

    ST flags noted for some GI agents

    Certain gastrointestinal and other agents (for example, esomeprazole oral packet, pantoprazole tablet) include 'ST' flags; step therapy protocols apply to these products.

    Step Therapy

    ST requires documented failure/intolerance

    Step therapy applies to drugs listed with 'ST' in Requirements & Limits; providers must document failure or intolerance to required prior agents when ST is enforced.

    Step Therapy

    Biologics/specialty agents may have ST

    Multiple biologic and specialty agents list 'ST' indicating they are subject to step therapy prior to approval; include trial history in PA requests for those agents.

    Step Therapy

    ST flagged for select ophthalmic agents

    Step therapy flags appear for select agents (example: tafluprost (pf) annotated with ST and QL); follow the formulary’s ST requirements when requesting coverage.

    Note

    Index — no step therapy details

    This index fragment does not list step therapy rules; review the specific drug policy pages for ST requirements where applicable.

    Documentation Required

    Provide clinical documentation when PA/QL/ST/SP flags present

    Medication entries marked with letters such as PA, QL, SP, or ST indicate coverage requirements; providers must supply the clinical information requested by the payer when submitting prior authorization requests.

    Documentation Required

    Verify coverage and PA/QL/ST requirements

    Providers and members should verify current coverage, PA requirements, and quantity limits by calling the toll‑free number on the member ID card or by visiting the plan member website before prescribing or dispensing.

    Documentation Required

    Follow formulary Requirements & Limits annotations

    Requirements & Limits annotations (PA, ST, QL, SP, H‑PA) on formulary lines imply documentation and administrative steps must be provided per the formulary when those designations are present.

    Documentation Required

    Documentation expectations for PA/QL/ST/SP

    When products are marked PA, QL, ST, or SP, documentation supporting medical necessity, prior therapy, or specialty handling is required as part of the authorization process.

    Documentation Required

    Examples where PA, QL, SP documentation required

    Some agents (example: DUPIXENT) are annotated with multiple flags such as 'PA, QL, SP', indicating that prior authorization, quantity‑limit compliance, and specialty program documentation must be provided.

    Documentation Required

    Submit PA and specialty/QL documentation where flagged

    Entries listing 'Requirements & Limits = PA, QL, SP' indicate prior authorization, quantity limits, and specialty pharmacy requirements apply; providers must submit PA and supporting documentation where indicated.

    Documentation Required

    Document generic substitution/product equivalence

    Some products are noted as generic equivalents and have QL requirements; documentation should indicate appropriate substitution or justification when applicable.

    Documentation Required

    Include QL and specialty distribution details in PA

    Drugs flagged with combinations like 'PA, QL, SP' require prior authorization and may have quantity limits and specialty distribution requirements; include all relevant clinical information when requesting approval.

    Documentation Required

    Provide diagnosis and prior therapy evidence for PA

    Prescribers must supply diagnosis, prior therapies attempted, and other clinical information to support PA, quantity limit, and specialty pharmacy requirements when those flags appear on a formulary entry.

    Documentation Required

    Ensure PA submission meets documentation and QL limits

    Providers must provide the information necessary to meet prior authorization requirements where PA is listed, and ensure dispensed quantity complies with any QL annotations.

    Denial Risk

    Denial risk when lower‑cost alternatives exist

    Medications may be excluded or denied when lower‑cost covered options exist or formulary choices favor lower‑cost alternatives; providers should review benefit plan documents and discuss lower‑cost options with patients.

    Denial Risk

    PA/QL may trigger denial if not obtained

    Prior authorization (PA) or quantity limits (QL) are specified for many listed drugs; failing to obtain PA or to comply with QL as required may result in coverage denial.

    Denial Risk

    Failure to meet Requirements & Limits may cause denial

    Drugs with Requirements & Limits that include PA, ST, QL, or SP may be denied if those conditions are not met; providers must follow the listed program requirements to avoid claim denial.

    Denial Risk

    PA and QL noncompliance can trigger denial

    Requests for products listed with 'PA' or 'H‑PA' may be subject to denial unless the PA conditions are met; exceeding quantity limits may result in partial fills or denial.

    Denial Risk

    PA/QL/ST/SP flags indicate potential denial triggers

    Drugs marked with PA, QL, ST, or SP may be denied if utilization management requirements are not satisfied; these flags indicate potential denial triggers during claims adjudication.

    Denial Risk

    Requirement flags may lead to denial or additional review

    Claims for drugs flagged with PA, QL, SP, ST, or NF may be denied or require additional review if the applicable program requirements are not met; verify flags before prescribing.

    Denial Risk

    Noncompliance with listed requirement types may cause denial

    Requests for drugs requiring PA, ST, QL, or SP may be denied when those program requirements are unmet; providers should confirm requirements and submit complete documentation to mitigate denial risk.

    Denial Risk

    Authorization flags can trigger administrative enforcement

    Entries marked with PA, ST, QL, SP, or NF indicate utilization management conditions that can trigger coverage denials or additional administrative actions if not satisfied.

    Denial Risk

    PA required for select ophthalmic/respiratory agents — denial risk

    Certain high‑tier or specialty ophthalmic and respiratory agents are listed with PA and may be denied if prior authorization is not obtained; obtain PA for these select agents to avoid denial.

    Denial Risk

    Specialty respiratory agents require PA/QL/SP — risk of denial

    Many pulmonary hypertension and specialty respiratory agents (examples: ADEMPAS, OPSUMIT, TYVASO) are annotated with PA, QL, and SP; claims may be denied without meeting those program requirements.

    Denial Risk

    Utilization management enforcement may cause denials

    Requests may be denied if the payer’s utilization management rules (PA, QL, SP) are not followed for listed drugs; providers should ensure compliance with these requirements.

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Key Terms & Abbreviations

    PDL formatting and purpose
    PurposePreferred Drug List (PDL) lists commonly prescribed medications by therapeutic class and places them into tiers representing member out-of-pocket cost
    Formatting conventionBrand-name drugs are shown in UPPERCASE while generics are shown in lowercase
    OrganizationMedications are grouped by common categories/classes and listed alphabetically within each group
    PDL — Preferred Drug List
    DefinitionPDL (Preferred Drug List): formulary of covered prescription medications with tiering and requirements
    UseShows tier placement and any per-line Requirements & Limits (e.g., PA, QL, ST, SP, NF)
    AuthorityBenefit plan documents govern if differences exist between PDL and plan terms
    PA — Prior Authorization
    DefinitionPrior Authorization (PA): a coverage requirement indicated on the formulary that requires payer approval before the drug is covered
    Where usedPA appears in Requirements & Limits next to many formulary entries (examples: HARVONI, LEDIPASVIR-SOFOSBUVIR, specialty biologics)
    ConsequenceClaims may be denied or require additional review if PA is not obtained when listed
    ST — Step Therapy
    DefinitionStep Therapy (ST): a utilization management requirement that a patient must try and fail specified preferred therapy(ies) before coverage of the listed drug
    ImplementationST is enforced via prior authorization; some entries show explicit step numbers (e.g., nicotine products with step 1/2/3)
    DocumentationPrescribers must document trials/failures or intolerance to required prior agents when ST is present
    QL — Quantity Limits
    DefinitionQuantity Limits (QL): restrictions on the amount of a medication that may be dispensed over a specified time period; noted in Requirements & Limits
    PrevalenceMany formulary entries include QL flags (examples: fluconazole, various antivirals, topical agents)
    EffectExceeding QL may result in partial fills or claim denial unless prior authorization or exception is obtained
    SP — Specialty drug designation
    DefinitionSP (Specialty): designation for specialty medications that often require specialty pharmacy distribution and handling
    ExamplesMultiple high-cost biologics and injectables are listed with SP (e.g., ADYNOVATE, NGENLA, NORDITROPIN FLEXPRO, NUCALA)
    Site of careSpecialty medications are generally managed through a specialty pharmacy and may require special handling and distribution channels
    H-PA — Higher-level prior authorization
    DefinitionH-PA: higher-level prior authorization or specialty/higher clinical review flag used in Requirements & Limits
    Usage noteDocument shows H-PA/H flags on select agents indicating elevated review requirements, but the excerpt does not provide a full procedural definition
    ImplicationRequests for products with H-PA may require additional clinical documentation and review beyond standard PA
    PA — (short)
    Short defPA — Prior Authorization: requires approval before coverage
    Where seenUsed as an administrative flag in Requirements & Limits across the PDL
    Provider actionSubmit PA request per payer process when PA is listed
    QL — (short)
    Short defQL — Quantity Limit: restrictions on the amount dispensed per time period
    Where seenCommonly annotated in Requirements & Limits for many agents (topicals, antivirals, specialty drugs)
    ImpactMay limit refill quantity or frequency without PA or exception
    ST — (short)
    Short defST — Step Therapy: trial of preferred therapy required before approval of the requested medication
    Where seenDisplayed as 'ST' in Requirements & Limits for select ophthalmic, GI, antiviral and biologic agents
    Provider requirementDocument prior trials/failures when submitting for ST medications
    SP — (short)
    Short defSP — Specialty Pharmacy designation: indicates specialty handling or distribution is required
    Where seenAppears on many high-cost injectables and biologics in Requirements & Limits
    ActionPrescribers and pharmacies should follow specialty channel and dispensing instructions when SP is listed
    PA — Prior Authorization (repeated)
    Definition (repeated)Prior Authorization (PA): coverage contingent on prior approval by the payer; listed in Requirements & Limits
    ExamplesPA appears alongside many entries (e.g., fluconazole: PA, ST, QL; VFEND: QL)
    Provider instructionObtain PA per payer process before dispensing when PA is indicated
    QL — Quantity Limit (repeated)
    Definition (repeated)Quantity Limit (QL): maximum allowed quantity per time period; indicated in Requirements & Limits
    ExamplesLANOXIN entries, antiviral agents, and topical therapies show QL flags in the excerpt
    Operational noteRefer to plan-specific QL tables for exact limits where annotated
    ST — Step Therapy (repeated)
    Definition (repeated)ST — Step Therapy: requires trial of preferred agents before the requested drug is approved; enforced via PA
    ExamplesEsomeprazole packet, pantoprazole entries, and select biologics are annotated with ST
    DocumentationPrescribers must document failure or intolerance to prior agents for ST review
    SP — Specialty Program (repeated)
    Definition (repeated)SP — Specialty Program/Pharmacy: managed specialty pharmacy requirements for distribution and handling
    ExamplesMany injectables and high-cost products show SP or SP+PA+QL in Requirements & Limits
    ImplicationClaims may require specialty dispensing; see specialty pharmacy process for fulfillment
    PA — Prior Authorization (admin flag)
    Admin flagPA — Prior Authorization indicated as an administrative requirement in the 'Requirements & Limits' column
    EffectPA-listed drugs require submission of PA prior to coverage; failure to obtain may result in denial
    Where to verifyProviders should verify PA requirements via member website or toll-free number on member ID card
    QL — Quantity Limit (admin flag)
    Admin flagQL — Quantity Limit indicated in Requirements & Limits for many formulary lines
    Document referenceSpecific QL values are provided in plan-specific QL tables referenced by the formulary
    Clinical effectPharmacies may be limited to QL quantities without PA or exception
    SP — Specialty Pharmacy designation (admin flag)
    Admin flagSP — Specialty Pharmacy designation used as an administrative flag where specialty distribution is required
    ImpactSpecialty items may require dispensing through designated specialty pharmacies and additional documentation
    ExamplesADYNOVATE, NGENLA, NORDITROPIN FLEXPRO and many biologics show SP or SP+PA+QL
    NF — Non-Formulary
    FlagNF — Non-Formulary flag appears on some entries indicating the product is not on the formulary
    ConsequenceNon-formulary drugs may require exception or may not be covered under the standard pharmacy benefit
    ExampleB IBRANCE ORAL TABLET is listed as NF with additional requirements noted
    Prior Authorization — PA / QL / ST flags
    PAPrior Authorization — PA flag appears next to many drug entries to denote pre-approval requirement
    QLQuantity Limit — QL flag indicates limits on dispensing quantity for the entry
    STStep Therapy — ST flag indicates step requirements apply before approval
    Quantity Limit — QL
    QLQuantity Limit — QL annotations appear for many agents, including topical, antiviral, and specialty products
    Provider checkRefer to the plan member website or member ID card to verify exact QL values and enforcement
    ExamplesLANOXIN, fluconazole, EPCLUSA, HARVONI are shown with QL in the excerpt
    Step Therapy — ST
    STStep Therapy — ST appears in Requirements & Limits for selected agents and requires trial of preferred therapy prior to coverage
    ExamplesHARVONI, LEDIPASVIR-SOFOSBUVIR, esomeprazole packets and some biologics show ST flags
    Provider actionDocument prior therapy trials when submitting for ST drugs
    Specialty distribution requirement — SP
    SPSpecialty distribution requirement — SP indicates specialty handling or distribution is required for coverage
    ExamplesMultiple high-cost injectables and biologics in the excerpt are flagged SP (e.g., B ADYNOVATE, NUCALA, NGENLA)
    Operational noteSpecialty items may also carry PA and QL flags; follow specialty pharmacy procedures when SP is present
    Non-Formulary — NF
    NFNon-Formulary — NF flag indicates some products are off-formulary in this excerpt
    EffectNF items may be subject to non-coverage or require prior authorization/exception processes
    ReferenceSee benefit plan documents for coverage stance on NF products
    Unknown flag 'H' (present without definition)
    Unknown 'H' flag'H' or 'H-PA' appears in Requirements & Limits for some entries but the excerpt does not provide a full definition
    ContextUsed alongside PA or QL on select agents (e.g., exemestane, various hormone products) suggesting higher review level
    ActionTreat 'H' as an elevated review indicator and follow payer instructions or contact the plan for clarification
    PA — Prior Authorization annotated
    PA next to entriesPA is frequently annotated next to drug lines to indicate prior authorization requirement prior to coverage
    ExamplesMany analgesics, antivirals, and specialty agents in the excerpt show PA in Requirements & Limits
    Provider resourceVerify PA process via member website or the toll-free number on the member ID card
    QL — Quantity Limits indicated
    QL indicationQuantity Limits (QL) are indicated for many products within the excerpt
    ExamplesAntivirals (EPCLUSA, HARVONI), topical agents, and certain oral tablets show QL flags
    Where to find limitsSpecific numeric QL values are maintained in plan-specific QL tables referenced by the formulary
    SP — Specialty Pharmacy requirement
    SP annotationSP appears as a utilization management flag for specialty medications and indicates specialty pharmacy requirements
    ExamplesEntries such as B ADYNOVATE, NUCALA, and NORDITROPIN FLEXPRO include SP in Requirements & Limits
    Provider stepsFollow specialty channel and documentation requirements when SP is present
    ST — Step Therapy noted
    ST flagST — Step Therapy flag is used for some agents; where present, prior trials are required before approval
    ExamplesFluconazole (PA, ST, QL), esomeprazole packets (PA, ST, QL), and certain antivirals display ST annotations
    DocumentationProviders must document prior therapy trials or reasons for bypassing steps when submitting PA for ST drugs
    PA — Prior Authorization utilization management
    PA utilization flagPA is used as a utilization management flag indicating prior approval is required for coverage
    ScopeAppears across therapeutic classes including antivirals, biologics, ophthalmics, and respiratory agents
    Denial riskFailure to obtain PA where required may result in claim denial
    QL — Quantity Limit utilization management
    QL utilization flagQL indicates utilization management limits on quantity dispensed and appears widely across the PDL excerpt
    ExamplesLANOXIN, EPCLUSA, HARVONI and many topical and specialty items are annotated with QL
    Operational notePharmacies should enforce QL limits unless PA or exception is obtained
    SP — Specialty Pharmacy utilization management
    SP utilization flagSP indicates specialty pharmacy utilization management for selected high-cost agents
    ExamplesNumerous biologics and specialty injectables carry SP flags in Requirements & Limits
    FulfillmentSpecialty fulfillment channels and documentation are typically required for SP drugs
    Drug index
    Index purposeDrug index maps drug/product names to internal page or section numbers within the larger policy document
    Excerpt contentThe provided index pages list cross-references for multiple products (e.g., APRISO, BENEFIX) in the document
    UseUse the index to locate the full formulary entry and any associated Requirements & Limits or coverage notes
    Index (drug/product)
    Index (drug/product)Index section lists drug/product names and page references for locating full formulary entries
    ScopeIndex contains many product entries and cross-references within the PDL document
    NoteIndex excerpt does not include coverage rules; refer to the corresponding formulary pages

    Step Therapy Policies & Affected Products

    RequirementWhat provider must document
    Step therapy (ST) enforced via prior authorization
    Documentation of trials (and failure or intolerance) of the required lower‑cost/preferred agent(s) as specified in the formulary prior to approval
    Product / EntryStep designation
    NICORETTE MOUTH/THROAT LOZENGE (B NICORETTE) - formulary lines show nicotine step 1
    NICORETTE STARTER KIT / nicotine polacrilex mouth/throat - entries reference step designations including step 1 and step 2 (and step 3 in related mapping)
    ST flag contextRequired documentation
    Formulary entries annotated with 'ST' (e.g., fluconazole oral listed with Requirements & Limits = PA, ST, QL)
    Provider must document trial and failure or intolerance to the specified preferred agent(s) when submitting prior authorization
    Example productST noted / action
    HARVONI ORAL TABLET - Requirements & Limits = PA, ST, QL, SP
    LANOXIN ORAL TABLET (certain strengths) - Requirements & Limits = PA, ST, QL (ST applies to listed strengths)
    General observationImplication for prior trials
    Multiple formulary lines include an 'ST' flag indicating step therapy applies
    When 'ST' is present, coverage is contingent on documented trials of required preferred therapies submitted with the prior authorization request
    GI agent / exampleST annotation
    esomeprazole magnesium oral packet - Requirements & Limits = PA, ST, QL
    pantoprazole sodium oral tablet (delayed release) - Requirements & Limits include PA, ST, QL, SP on some lines
    Where ST appearsHow applied
    ST appears in the Requirements & Limits field on formulary entries across therapeutic classes
    ST is enforced via the prior authorization process; providers must document required prior therapy when ST is listed
    Agent examples (biologic/specialty)ST presence
    OMNITROPE - Requirements & Limits = PA, ST, QL, SP (ST noted on some lines)
    ORIAHNN and other specialty biologics - entries include ST among other requirement flags indicating step therapy may apply prior to approval
    Ophthalmic agentST flag / other limits
    tafluprost (pf) and similar ophthalmic glaucoma agents - listed under Ophthalmic Agents - Drugs for Glaucoma
    Formulary shows QL and ST for select ophthalmic lines (ST noted where applicable) — step therapy applies when ST is present

    Quantity Limits & Affected Products

    Quantity limits (multiple)
    Multiple QL applicationsQuantity limits (QL) apply to many listed products across therapeutic classes in the excerpt
    Where shownQL flags appear in the Requirements & Limits column for topical, antiviral, specialty, and oral agents
    Action for providersVerify numeric QL values on the plan-specific QL tables when planning therapy or refills
    Quantity limit — fluconazole oral
    Productfluconazole (oral) — Requirements & Limits = PA, ST, QL
    ImplicationProvider must obtain PA and document step therapy/compliance with QL where indicated
    VerificationCheck plan resources for specific QL numeric limits
    Posaconazole oral tablet DR — PA, ST, QL
    Productposaconazole oral tablet delayed release — Requirements & Limits = PA, ST, QL
    TieringPosaconazole appears at multiple tier placements with PA/ST/QL annotations in the excerpt
    Provider actionObtain PA and document prior therapy failures per ST; verify QL specifics in plan QL tables
    Antiviral/hepatitis agents — QL noted
    ProductsEPCLUSA, HARVONI, LEDIPASVIR-SOFOSBUVIR, SOFOSBUVIR-VELPATASVIR, MAVYRET, VOSEVI — QL indicated (many also show PA/SP/ST)
    ImplicationAntiviral/hepatitis agents are subject to QL and frequently require PA and specialty handling
    Provider stepSubmit PA and follow QL and ST requirements when treating hepatitis C agents
    LANOXIN oral tablet — PA/ST/QL
    ProductLANOXIN oral tablet — Requirements & Limits include PA, ST, QL on certain strengths
    DetailDifferent strengths show varying tier and requirement assignments (some strengths flagged with PA/ST/QL)
    Provider adviceVerify strength-specific Requirements & Limits before dispensing to ensure compliance
    Multiple entries marked QL
    ObservationMultiple formulary entries across the excerpt are annotated with QL — see the formulary rows for specific items
    ExamplesTopical agents, oral tablets, and specialty injectables show QL flags in many sections
    ReferencePlan-specific QL tables should be consulted for numeric limits and enforcement details
    Entries marked with 'QL' — see plan-specific tables
    Formulary noteEntries marked 'QL' in the document refer users to plan-specific QL tables for exact limits
    ScopeQL annotations are present across therapeutic classes in the excerpt
    Provider actionCheck the PDL QL tables or member website for numeric limits prior to prescribing or dispensing
    ANNOVERA — QL
    ProductANNOVERA — Requirements & Limits = QL
    TierListed at Tier = 3 in the excerpt
    ActionConfirm QL numeric limits in the plan QL tables when prescribing or dispensing
    NORDITROPIN FLEXPRO — QL / PA / SP
    ProductNORDITROPIN FLEXPRO — Requirements & Limits = PA, QL, SP (PA/QL/SP noted)
    ImplicationRequires specialty handling and may require prior authorization and quantity restrictions
    Provider stepSubmit PA and use specialty pharmacy channel as indicated; verify QL values in plan tables
    TERIPARATIDE solution pen — PA / SP / QL (varies)
    ProductTERIPARATIDE SOLUTION PEN-INJECTOR 560 mcg/2.24 ml — Requirements & Limits vary by line item (PA, SP or QL may apply)
    ImplicationSome presentations may require prior authorization or specialty dispensing while others are subject to quantity limits
    Provider actionConfirm the specific line-item requirements (PA, SP, QL) for the exact product and strength before prescribing
    Multiple entries flagged — QL applies where annotated
    GeneralMultiple entries across the excerpt are flagged with QL (quantity limits); consult the QL flag and plan QL tables for details
    Therapeutic breadthQL applies to topical, antiviral, hormonal, ophthalmic, respiratory and many specialty products in this excerpt
    Provider instructionRefer to the PDL and plan-specific QL documentation when planning treatment or refill quantities

    Specialty Pharmacy & Site-of-Care Management

    Note

    Background & Rationale

    Specialty medications are high-cost agents used to treat rare or complex conditions and are commonly managed through a specialty pharmacy. These products often require special handling, distribution channels, and additional administrative requirements such as prior authorization or specialty program management; consult the plan's specialty pharmacy processes when prescribing or dispensing specialty agents.